Healios K.K. Stock price

Equities

4593

JP3835100003

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
150 JPY +7.14% Intraday chart for Healios K.K. +13.64% -9.09%
Sales 2023 121M 799K Sales 2024 * 910M 6.01M Capitalization 13.52B 89.27M
Net income 2023 -3.82B -25.24M Net income 2024 * -2.69B -17.78M EV / Sales 2023 82.5 x
Net Debt 2023 2.31B 15.28M Net cash position 2024 * 822M 5.43M EV / Sales 2024 * 14 x
P/E ratio 2023
-2.93 x
P/E ratio 2024 *
-4.52 x
Employees 71
Yield 2023 *
-
Yield 2024 *
-
Free-Float 62.6%
More Fundamentals * Assessed data
Dynamic Chart
1 day+7.14%
1 week+13.64%
Current month+10.29%
1 month+13.64%
3 months-14.77%
6 months-35.62%
Current year-9.09%
More quotes
1 week
138.00
Extreme 138
152.00
1 month
127.00
Extreme 127
155.00
Current year
114.00
Extreme 114
170.00
1 year
114.00
Extreme 114
344.00
3 years
114.00
Extreme 114
2 557.00
5 years
114.00
Extreme 114
2 557.00
10 years
114.00
Extreme 114
2 669.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 11-02-23
Director of Finance/CFO 47 18-02-28
Chief Tech/Sci/R&D Officer 42 12-03-31
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 71 18-02-28
Director/Board Member 54 22-03-31
More insiders
Date Price Change Volume
24-03-28 150 +7.14% 1 258 300
24-03-27 140 -2.10% 1,174,900
24-03-26 143 -2.72% 1,088,900
24-03-25 147 -2.65% 1,065,800
24-03-22 151 +3.42% 2,286,800

Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT

More quotes
HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
150 JPY
Average target price
280 JPY
Spread / Average Target
+86.67%
Consensus
  1. Stock
  2. Equities
  3. Stock Healios K.K. - Japan Exchange